Seattle Genetics and Pieris pharmaceutical Collaboration Agreement
Pieris Pharmaceuticals (PIRS) and Seattle Genetics (SGEN) signed a multi-program immuno-oncology collaboration agreement intended to evaluate novel bi-specific immuno-oncology agents. These agents would combine Pieris’ Anticalin proteins drugs with Seattle Genetics’ targeted antibodies to develop multiple targeted bi-specific immuno-oncology treatments for both solid and blood cancers.
Pieris Pharmaceuticals created recombinant engineered Anticalin protein-based therapeutics. These proteins are versions of the human protein lipocalin, which naturally bind, store and . . .